Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Avm Biotechnology LLC is currently managing a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The company has 2 pending office actions, which are distributed across 2 distinct art units. This distribution indicates that the company's active applications are being reviewed in different technical categories within the biotechnology field. The prosecution involves 2 distinct examiners, providing different points of contact at the USPTO.
HAVLIN, ROBERT H is the busiest examiner for the company and is responsible for 1 busiest examiner pending action. This means that HAVLIN, ROBERT H handles a portion of the 2 pending office actions currently active for the company. With 2 distinct art units and 2 distinct examiners involved, the portfolio's workload is not concentrated under a single individual. The focus on Biotechnology & Pharmaceuticals requires navigating specific regulatory and technical hurdles across these areas.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAVLIN, ROBERT H | 1 | 51.5% | +28.1% |
| SANG, HONG | 1 | 55.0% | +62.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17921128 | Glucocorticoid Receptor (GR) Modulators for Treating a SARS-COV-2 Virus | HAVLIN, ROBERT H | 23d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17921128 | Glucocorticoid Receptor (GR) Modulators for Treating a SARS-COV-2 Virus | HAVLIN, ROBERT H | 23d overdue |
| 17542712 | Replacement of Cytotoxic Preconditioning Before Cellular Immunotherapy | SANG, HONG | 14d |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17921128 | Glucocorticoid Receptor (GR) Modulators for Treating a SARS-COV-2 Virus | HAVLIN, ROBERT H | 1626 | §103§112Other | Final Rejection | 23d overdue | Pending | Oct 25, 2022 |
| 17542712 | Replacement of Cytotoxic Preconditioning Before Cellular Immunotherapy | SANG, HONG | 1646 | §112 | Final Rejection | 14d | Pending | Dec 06, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial